Across TCGA pan-cancer cohorts, RNU6-816P RNA is linked to patient survival in 1 of 34 cancer types, making it the most broadly survival-associated RNU6-816P data layer.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RNU6-816P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-816P expression acts as an unfavorable survival marker.
STAD are the cancer types where RNU6-816P RNA most reproducibly stratifies survival.